Drreddys Laboratories | RDY - Operating Profit


Drreddys Laboratories reported INR12.81B in Operating Profit for its fiscal quarter ending in September of 2026.





Operating Profit Change Date
ANI Pharmaceuticals USD 51.84M 12M Sep/2026
Aurora Cannabis CAD -8.73M 1.3M Jun/2026
Bayer EUR 129M 698M Sep/2026
Canopy Growth CAD -17.58M 9.9M Jun/2026
Cipla INR 10.43B 1.55B Sep/2026
Corcept Therapeutics USD 114.72M 73.42M Sep/2026
Drreddys Laboratories INR 12.81B 11.98B Sep/2026
GlaxoSmithKline GBP 2.86B 251M Sep/2026
Hikma Pharmaceutical USD 348M 161M Dec/2025
Lonza CHF 673M 243M Jun/2025
Novartis USD 5.14B 392M Sep/2026
Pacira USD 2.57B 2.56B Sep/2026
Phibro Animal Health USD 54.99M 2.36M Dec/2025
Prestige Brands USD 52.52M 22.97M Jun/2026
Richter Gedeon HUF 76.16B 13.84B Jun/2026
Sun Pharmaceuticals INR 39.07B 3.5B Sep/2026
Supernus Pharmaceuticals USD -21.04M 14.21M Jun/2026
Teva Pharmaceutical Industries USD 1.19B 954M Sep/2026